netazepide

DRUG2 trials

Sponsors

Trio Medicines Ltd., University of Cape Town

Conditions

DyspepsiaECL-cell HyperplasiaMusculoskeletal DiseasesParietal-cell HyperplasiaRebound Hyperacidity

Phase 1

Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin

CompletedNCT02620696

Trio Medicines Ltd.Dyspepsia, ECL-cell Hyperplasia, Parietal-cell Hyperplasia +1

Start: 2009-11-30End: 2010-09-30Updated: 2015-12-03

Phase 3

A Randomized, Double Blind, Single Centre, study to assess the efficacy, safety and tolerability of the Gastrin Receptor Antagonist (GRA), Netazepide administered for 90 days, in post-menopausal women (OSTEO-GRA)

Active, not recruitingPACTR202407466904092

University of Cape TownMusculoskeletal Diseases

Start: 2019-04-01Target: 90Updated: 2026-08-03